Edith M.G. van Esch

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Mariëtte I.E. van Poelgeest, Marij J.P. Welters, Edith M.G. van Esch et al. · Journal of Translational Medicine · 2013 · 187 citations · Full text

Medicine, Immunology, Oncology +17

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

Mariëtte I.E. van Poelgeest, Marij J.P. Welters, Renee Vermeij et al. · Clinical Cancer Research · 2016 · 165 citations

Medicine, Immunology, Oncology +17

The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation

Bart Tummers, Renske Goedemans, Laetitia P.L. Pelascini et al. · Nature Communications · 2015 · 79 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Clinical Characteristics Associated With Development of Recurrence and Progression in Usual-Type Vulvar Intraepithelial Neoplasia

Edith M.G. van Esch, Maija C.I. Dam, Michelle Osse et al. · International Journal of Gynecological Cancer · 2013 · 57 citations

Medicine, Oncology, Pathology +17

Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV‐induced vulvar neoplasia

Edith M.G. van Esch, Mariëtte I.E. van Poelgeest, J. Baptist Trimbos et al. · International Journal of Cancer · 2014 · 51 citations · Full text

Medicine, Oncology, Pathology +17